PACC

Black Diamond Therapeutics Presents Novel Real-World Evidence of the Evolving EGFR Mutation Landscape in NSCLC and the Opportunity for BDTX-1535 in an Oral Presentation at the 2024 American Association of Cancer Research Annual Meeting

Retrieved on: 
Sunday, April 7, 2024
Diamond, EGFR, Helmy Eltoukhy, Mutation, Prevalence, NSCLC, Survival, Foundation Medicine, Patient, Cancer, Lung cancer, AACR, PACC, TKI, Drug resistance, MD Anderson Cancer Center, Associate professor

CAMBRIDGE, Mass., April 07, 2024 (GLOBE NEWSWIRE) -- Black Diamond Therapeutics, Inc. (Nasdaq: BDTX), a clinical-stage oncology company developing MasterKey therapies that target families of oncogenic mutations in patients with cancer, presented real-world evidence of the evolving epidermal growth factor receptor (EGFR) mutation landscape in non-small cell lung cancer (NSCLC), and the potential of BDTX-1535 to address a broader range of mutations compared to existing therapies. The results were disclosed in an oral presentation on April 7, 2024, at the 2024 American Association of Cancer Research (AACR) Annual Meeting held in San Diego, California.

Key Points: 
  • The results were disclosed in an oral presentation on April 7, 2024, at the 2024 American Association of Cancer Research (AACR) Annual Meeting held in San Diego, California.
  • The analyses reveal a broad spectrum of non-classical mutations, as well as an increased prevalence of the acquired resistance mutation, C797S.
  • The compound also potently inhibits the drug resistance C797S mutation, which emerges following treatment with third-generation EGFR inhibitors, including osimertinib.
  • Black Diamond is currently advancing BDTX-1535 in a Phase 2 trial for patients with EGFRm NSCLC across multiple lines of therapy.

ArriVent BioPharma Reports Full Year 2023 Financial Results

Retrieved on: 
Thursday, March 28, 2024
Research, EGFR, Conference, Breakthrough therapy, NSCLC, Patient, Food and Drug Administration, Lung cancer, Therapy, PACC, Safety, ADC, FDA, SHP2, Food, Pharmaceutical industry

In September 2023, ArriVent and its partner, Shanghai Allist Pharmaceuticals Company, Ltd. ("Allist”), presented interim Phase 1b results at the World Conference on Lung Cancer.

Key Points: 
  • In September 2023, ArriVent and its partner, Shanghai Allist Pharmaceuticals Company, Ltd. ("Allist”), presented interim Phase 1b results at the World Conference on Lung Cancer.
  • In January 2024, ArriVent appointed Winston Kung as Chief Financial Officer and Treasurer, bringing over 20 years of extensive leadership experience, most recently as Chief Financial Officer and Chief Operating Officer at PMV Pharmaceuticals.
  • Research and development expenses were $64.9 million and $30.4 million for the years ended December 31, 2023 and 2022, respectively.
  • Net loss was $69.3 million and $37.0 million for the years ended December 31, 2023 and 2022, respectively.

InnoCare Announces Dosing of First Patient in Clinical Study of the Combination of SHP2 Inhibitor ICP-189 and EGFR Inhibitor Furmonertinib

Retrieved on: 
Friday, March 29, 2024
Biotechnology, Health, Pharmaceutical, Clinical Trials, Oncology, Lung cancer, EGFR, SRC, NSCLC, Patient, Breakthrough therapy, Trial of the century, DLT, Clinical trial, PACC, HKEX, FDA, SHP2, Food, Pharmaceutical industry

In July 2023, InnoCare and ArriVent BioPharma, Inc. (Nasdaq: AVBP) announced a clinical development collaboration, accelerating the clinical trial of ICP-189 in combination with furmonertinib in patients with advanced or metastatic NSCLC in China.

Key Points: 
  • In July 2023, InnoCare and ArriVent BioPharma, Inc. (Nasdaq: AVBP) announced a clinical development collaboration, accelerating the clinical trial of ICP-189 in combination with furmonertinib in patients with advanced or metastatic NSCLC in China.
  • Furmonertinib is being advanced by ArriVent in global studies in patients with advanced or metastatic NSCLC with EGFR mutations, including exon 20 insertion mutations.
  • Furmonertinib is also being evaluated for the treatment of NSCLC patients with EGFR P-loop alpha-c helix compressing (PACC) mutations.
  • We will accelerate the clinical study and expect this innovative therapy to benefit more NSCLC patients early.”

The Pawfect Match: Petco Love and BOBS from Skechers™ Celebrate National Matchmaker Day

Retrieved on: 
Tuesday, August 29, 2023
Volunteering, Love, Partnership, Magic, Intuition, Organization, Animal, Euthanasia, SAN, Dog, PACC, Pet, Matchmakers, Family, Petco, Cat

SAN ANTONIO, Aug. 29, 2023 /PRNewswire/ -- Making a perfect love match is no easy task, but animal shelter and rescue workers across the U.S. play cupid every day and find adoptable shelter pets their new, loving homes and families. Petco Love, a national nonprofit, and BOBS from Skechers™, are celebrating the lifesaving work done by animal welfare professionals on August 31st, National Matchmaker Day.

Key Points: 
  • Petco Love , a national nonprofit, and BOBS from Skechers™, are celebrating the lifesaving work done by animal welfare professionals on August 31st, National Matchmaker Day.
  • National Matchmaker Day is not just about romantic connections; it's also an opportunity to highlight the incredible work being done to find loving homes for pets in need.
  • Petco Love has helped find loving homes for over 6.7 million pets and counting, in partnership with Petco and more than 4,000 organizations.
  • To date, Petco Love has invested more than $350 million in adoption and other lifesaving efforts.

2023 Prefect Associate Certification Course (PACC) Dates Announced for Data Practitioners and Professionals

Retrieved on: 
Tuesday, January 10, 2023
Prefect, Certification, PACC, Industrial, SVP, Collaboration, Success, Cox Automotive, Industrial engineering, Online shopping

WASHINGTON, Jan. 10, 2023 /PRNewswire/ -- Prefect Technologies, Inc, the company behind the open-source data workflow automation platform Prefect, today announced upcoming dates for its Prefect Associate Certification Course (PACC). In this two-day course, participants learn how to orchestrate and observe their dataflows—saving their organizations time, money, and complexity. By attending the course, participants will obtain their Prefect Associate Certification.

Key Points: 
  • In 2022, Prefect held four certification courses in the United States, educating over 100 data practitioners.
  • In 2023, Prefect will expand PACC to an international audience with PACC-London in June.
  • "The best part about the Prefect Associate Certification Course is the tangible takeaways we've seen participants leave with: solutions they can implement immediately.
  • Our goal is to provide a space for new and existing Prefect users to build meaningful relationships in the data community.

Utilities Employees Credit Union Signs with Lumin Digital for Enhanced Digital Banking Services

Retrieved on: 
Wednesday, August 17, 2022
PACC, CEO, Technology, Science and technology in Asia, Research, PSCU, Luminous at Darling Quarter, SAN, Partnership, Safety, Automation, Digital Federal Credit Union, Credit union, Goal, Solution, Cryptocurrency, Online shopping

SAN RAMON, Calif., Aug. 17, 2022 /PRNewswire/ -- Lumin Digital announced today that Utilities Employees Credit Union (UECU) has signed a multi-year agreement for Lumin Digital's cloud-based online and mobile digital banking platform.

Key Points: 
  • SAN RAMON, Calif., Aug. 17, 2022 /PRNewswire/ -- Lumin Digital announced today that Utilities Employees Credit Union (UECU) has signed a multi-year agreement for Lumin Digital's cloud-based online and mobile digital banking platform.
  • A cloud-native digital banking platform, Lumin Digital will provide UECU members with an integrated, customized experience that matches larger financial institutions' offerings.
  • Lumin also enables credit unions to provide users with real-time updates and new features that add value and simplify everyday banking.
  • "Like UECU, Lumin Digital is passionate about providing members with innovative financial tools and experiences," said Jeff Chambers, founder and CEO of Lumin Digital.

GEODIS Wins "Inventory Management Innovation of the Year" Award by SupplyTech Breakthrough

Retrieved on: 
Wednesday, July 6, 2022
Supply, Express, Cycle count, Supply chain optimization, Workforce, Intelligence, PACC, Industry, Distribution, IC, Automation, Robotics, Risk, Technology, Freight forwarder, Institute of Transport Management, Inventory, WMS, Solution, AI, Time, Road transport, Leadership, Safety, Tech, IOT, Algorithm, Warehouse

GEODIS was recognized for its advanced approach to inventory counting: Predictive Analytics Cycle Counting (PACC).

Key Points: 
  • GEODIS was recognized for its advanced approach to inventory counting: Predictive Analytics Cycle Counting (PACC).
  • At GEODIS, we believe the relationship with the customer is crucial in creating that value as we work together to implement PACC.
  • A full list of all SupplyTech Breakthrough Award winners for 2022 can be found at www.supplytechbreakthrough.com .
  • The annual SupplyTech Breakthrough Awards provide public recognition for the achievements of SupplyTech companies and products in categories including Inventory Management, Supply Chain Visibility, Transportation Management, Material Handling, IoT and Robotics, and more.